Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

Lolamicin: The Selective antibiotic against Gram-negative infections that spares gut microbiome  

Current antibiotics used in clinical practice, in addition to neutralising target pathogens also harm healthy bacteria in the gut. The disturbance in gut microbiome has toxic effects on liver, kidney and other organs. This is an issue to be addressed. Researchers have discovered lolamicin, an antibiotic candidate that has been found to be effective against gram-negative infections without affecting healthy gut microbiome in pre-clinical studies. This is proof-of-concept that antibiotics that kill pathogenic microbes while sparing beneficial bacteria in the gut can be developed for gram-negative infections. It offers a hope for addressing problems associated with indiscriminate targeting of gram-negative bacteria. However, years of further research is needed before it reaches the stage of clinical use.  

Most antibiotics target only gram-positive bacteria or target both gram-positive and gram-negative bacteria. Some antibiotics specific to gram-negative bacteria (gram-negative bacteria have a double layer of protection in their cell wall which makes them difficult to kill) also kill beneficial gram-negative bacteria in the gut. The disturbances in the gut microbiome thus created are found to have toxic/adverse effects particularly on liver and kidney. Hence the need to develop antibiotics that could selectively kill the pathogenic bacteria while sparing the beneficial ones. As reported in a recent research paper, scientists have developed one such antibiotic called lolamicin that has been found to selectively target gram-negative pathogenic bacteria while sparing beneficial ones.  

Lolamicin is an inhibitor of Lol (localization of lipoproteins) pathway, a lipoprotein-transport system found exclusively in gram-negative bacteria that is genetically different in pathogenic and beneficial bacteria.  

In cell culture, it had no appreciable effect on gram-positive bacteria. At higher doses, it neutralised up to 90% of multidrug-resistant E. coli, K. pneumoniae and E. cloacae clinical isolates.   

Oral administration of lolamicin to mice with drug-resistant septicemia or pneumonia rescued 100% of the mice with septicemia and 70% of the mice with pneumonia. Further, lolamicin administration did not lead to any drastic shift in taxonomic composition of bacteria in gut microbiome of mice over the course of the three-day treatment or the following 28-day recovery.  

These results of pre-clinical animal studies are encouraging and offers a hope for addressing problems associated with indiscriminate targeting of gram-negative bacteria. It is is a proof of concept that it is possible to develop antibiotics that selectively target harmful gram-negative bacteria while sparing gut microbiome of any adverse effect. However, years of further research are needed to extend the findings.  

*** 

References:  

  1. Muñoz, K.A., Ulrich, R.J., Vasan, A.K. et al. A Gram-negative-selective antibiotic that spares the gut microbiome. Nature 630, 429–436 (2024). Published: 29 May 2024. DOI: https://doi.org/10.1038/s41586-024-07502-0 
  1. University of Illinois Urbana-Champaign 2024. Research news – New antibiotic kills pathogenic bacteria, spares healthy gut microbes. Posted 29 May 2024. Available at https://news.illinois.edu/view/6367/668002791  

*** 

SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

near-Earth asteroid 2024 BJ to make closest approach to Earth  

On 27 January 2024, an airplane-sized, near-Earth asteroid 2024 BJ will...

COVID-19 Crisis in India: What May Have Gone Wrong

The causative analysis of the current crisis in India...

Novel Drug Therapy to Cure Deafness

Researchers have successfully treated hereditary hearing loss in mice...
- Advertisement -
93,063FansLike
47,295FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe